Dipeptidyl peptidase-4 (DPP-4) inhibitors enhance the action of endogenous incretins, leading to a modest HbA1c reduction of 0.5–1.0%, with a neutral effect on body weight and a low risk of hypoglycemia [9]. Here, DPP4 is linked to Hypoglycemia.